ClinicalTrials.Veeva

Menu
E

Encore Medical Research, LLC | Hollywood, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
Orforglipron
LY3298176
LY3502970
Ixekizumab
Obeldesivir
SAR444656
Semaglutide
Amlitelimab
Sugar

Parent organization

This site is a part of Encore Medical Research, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

29 of 48 total trials

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants w...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Orforglipron

This is a parallel, Phase 2, 3-arm study to evaluate the efficacy, safety, PK, and biological effects of SAR444656 compared with placebo in adult par...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: SAR444656 (KT-474)
Locations recently updated

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type...

Enrolling
Type 2 Diabetes (T2D)
Drug: Placebo (NNC0487-0111 oral)
Drug: NNC0487-0111 oral
Locations recently updated

The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney funct...

Enrolling
Chronic Kidney Disease
Drug: Placebo
Drug: Semaglutide

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new invest...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Placebo

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml
Locations recently updated

The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overw...

Enrolling
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with...

Not yet enrolling
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequ...

Active, not recruiting
Type 2 Diabetes
Drug: Orforglipron
Drug: Placebo

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult part...

Active, not recruiting
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study wi...

Active, not recruiting
Obesity
Drug: Retatrutide
Drug: Tirzepatide

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Active, not recruiting
Vitiligo
Drug: Upadacitinib
Other: NB-UVB (narrow-band ultraviolet B) Phototherapy

This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism a...

Enrolling
Hypothyroidism
Drug: Levothyroxine
Drug: Armour Thyroid

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Active, not recruiting
NonSegmental Vitiligo
Drug: Placebo
Drug: Povorcitinib

This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Active, not recruiting
Dermatitis Atopic
Drug: Amlitelimab
Drug: Placebo

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participan...

Enrolling
Psoriasis
Overweight or Obesity
Drug: Tirzepatide

The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with at...

Enrolling
Atopic Hand and Foot Dermatitis
Drug: Lebrikizumab
Drug: Placebo

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication...

Begins enrollment this month
Chronic Kidney Disease
Drug: Placebo matching vicadrostat
Drug: Vicadrostat

Trial sponsors

Lilly logo
Novo Nordisk logo
Gilead Sciences logo
AbbVie logo
Sanofi logo
A
A
Boehringer Ingelheim logo
E
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems